Home KEYTRUDA (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma
 

Keywords :   


KEYTRUDA (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma

2015-03-11 01:01:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. EAMS Aims to Give U.K. Patients Access to Promising, Innovative Treatments Prior to European License KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the companys anti-PD-1 therapy, pembrolizumab, which is marketed in the U.S. under the name KEYTRUDA, is the first treatment to be accepted under the U.K.s new Early Access to Medicines Scheme (EAMS). Pembrolizumab was accepted under the scheme for the treatment of advanced melanoma based on the significance of the early study findings and unmet medical need. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor Contacts:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to for made advanced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11PM responds to Sir Alan Bates after repeated requests
05.11American Angus elects 2024-25 board leaders
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 8A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Brazil gives green light to medicinal use of Cannabis in animals
More »